1. VGF expression by T lymphocytes in patients with Alzheimer's disease
- Author
-
Sabrina Greiner-Bohl, Johann Steiner, Bernhard Bogerts, Stefan Busse, Roland Hartig, Ursula Bommhardt, Henrik Dobrowolny, Christian Mawrin, Mandy Busse, and Sarah Glorius
- Subjects
Male ,Gerontology ,medicine.medical_specialty ,CD3 Complex ,T-Lymphocytes ,CD3 ,T cell ,T cells ,Rivastigmine ,Flow cytometry ,Research Paper: Gerotarget (Focus on Aging) ,Cerebrospinal fluid ,Alzheimer Disease ,Internal medicine ,medicine ,Humans ,Nerve Growth Factors ,Cells, Cultured ,Aged ,Cell Proliferation ,Aged, 80 and over ,Glycated Hemoglobin ,Sirolimus ,VGF expression ,medicine.diagnostic_test ,biology ,rapamycin ,Cell growth ,business.industry ,Alzheimer's disease ,Flow Cytometry ,medicine.disease ,Neuroprotective Agents ,Endocrinology ,Nerve growth factor ,medicine.anatomical_structure ,Oncology ,biology.protein ,Female ,Cytokine secretion ,business ,Biomarkers ,Immunosuppressive Agents - Abstract
Secretion of VGF is increased in cerebrospinal fluid and blood in neurodegenerative disorders like Alzheimer's disease (AD) and VGF is a potential biomarker for these disorders. We have shown that VGF is expressed in peripheral T cells and is correlated with T cell survival and cytokine secretion. The frequency of VGF+CD3+ T cells increases with normal aging. We found an increased number of VGF-expressing T cells in patients with AD compared to aged healthy controls, which was associated with enhanced HbA1c levels in blood. Upon treatment with rivastigmine, T cell proliferation and VGF expression in AD patients decreased to the level found in controls. Moreover, rapamycin treatment in vitro reduced the number of VGF+CD3+ cells in AD patients to control levels.
- Published
- 2015